WealthPLAN Partners LLC grew its stake in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 240.9% during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 20,040 shares of the biopharmaceutical company’s stock after acquiring an additional 14,161 shares during the period. WealthPLAN Partners LLC’s holdings in Bristol-Myers Squibb were worth $1,268,000 as of its most recent SEC filing.
Other institutional investors also recently bought and sold shares of the company. W.G. Shaheen & Associates DBA Whitney & Co purchased a new position in shares of Bristol-Myers Squibb during the 1st quarter valued at $101,000. Institutional & Family Asset Management LLC bought a new stake in Bristol-Myers Squibb in the first quarter worth $106,000. Delphi Private Advisors LLC bought a new stake in Bristol-Myers Squibb in the fourth quarter worth $108,000. Centerpoint Advisors LLC boosted its holdings in Bristol-Myers Squibb by 373.1% in the first quarter. Centerpoint Advisors LLC now owns 1,774 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 1,399 shares in the last quarter. Finally, NuWave Investment Management LLC bought a new stake in Bristol-Myers Squibb in the fourth quarter worth $119,000. Institutional investors and hedge funds own 71.43% of the company’s stock.
A number of brokerages recently issued reports on BMY. BMO Capital Markets reiterated a “hold” rating and issued a $47.00 price objective on shares of Bristol-Myers Squibb in a report on Thursday, June 21st. ValuEngine cut shares of Bristol-Myers Squibb from a “hold” rating to a “sell” rating in a report on Wednesday, May 2nd. Barclays decreased their price objective on shares of Bristol-Myers Squibb from $65.00 to $55.00 and set an “equal weight” rating for the company in a report on Friday, April 27th. Credit Suisse Group set a $58.00 price objective on shares of Bristol-Myers Squibb and gave the stock a “hold” rating in a report on Thursday, April 26th. Finally, Jefferies Financial Group reiterated a “hold” rating and issued a $66.00 price objective on shares of Bristol-Myers Squibb in a report on Friday, April 13th. Three equities research analysts have rated the stock with a sell rating, thirteen have given a hold rating and seven have given a buy rating to the stock. Bristol-Myers Squibb presently has a consensus rating of “Hold” and an average target price of $62.84.
Bristol-Myers Squibb stock opened at $55.34 on Friday. The firm has a market cap of $90.39 billion, a price-to-earnings ratio of 18.39, a PEG ratio of 1.45 and a beta of 0.95. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.52 and a quick ratio of 1.39. Bristol-Myers Squibb Co has a fifty-two week low of $49.96 and a fifty-two week high of $70.05.
Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, April 26th. The biopharmaceutical company reported $0.94 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.85 by $0.09. The firm had revenue of $5.19 billion during the quarter, compared to analyst estimates of $5.25 billion. Bristol-Myers Squibb had a net margin of 4.37% and a return on equity of 37.56%. The business’s revenue was up 5.4% on a year-over-year basis. During the same quarter in the previous year, the business earned $0.84 EPS. equities analysts forecast that Bristol-Myers Squibb Co will post 3.42 earnings per share for the current fiscal year.
The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, August 1st. Stockholders of record on Friday, July 6th will be given a dividend of $0.40 per share. This represents a $1.60 dividend on an annualized basis and a dividend yield of 2.89%. The ex-dividend date is Thursday, July 5th. Bristol-Myers Squibb’s dividend payout ratio is currently 53.16%.
In related news, Director Dinesh C. Paliwal acquired 4,770 shares of the business’s stock in a transaction dated Monday, April 30th. The stock was acquired at an average price of $52.40 per share, with a total value of $249,948.00. Following the completion of the transaction, the director now owns 8,027 shares of the company’s stock, valued at $420,614.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. 0.23% of the stock is currently owned by corporate insiders.
About Bristol-Myers Squibb
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, and distributes biopharmaceutical products worldwide. The company offers drugs in the various therapeutic classes, such as oncology; cardiovascular; immunoscience; and virology, including human immunodeficiency virus (HIV) infection.
Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.